RxDoctor Payments Data

Rodney Laningham, MD

Family Medicine · Conroe, TXNPI 1821185703

Payments from drug & device makers

$7,348in general payments, 2019–2025

Across 370 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$783
  • Amgen$600
  • Dexcom, Inc.$554
  • AstraZeneca$409
  • Lilly USA, LLC$400
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$1,20016%
  • Food & beverage$6,13483%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,348 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$697,199
Medicare patients
1,075
Services billed
52,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$155,203
OzempicSemaglutide131$148,446
MounjaroTirzepatide61$89,409
JardianceEmpagliflozin40$48,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$41,645
XareltoRivaroxaban24$25,736
JanuviaSitagliptin Phosphate19$23,044
Repatha SureclickEvolocumab23$21,148
EntrestoSacubitril/Valsartan16$20,950
LinzessLinaclotide14$15,426
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$13,198
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$11,613
Levemir FlexpenInsulin Detemir18$7,109
Tresiba Flextouch U-200Insulin Degludec12$7,021
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$6,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$155,203155 claims
Novo NordiskOzempic$236$148,446131 claims
Lilly USA, LLCMounjaro$400$89,40961 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$245$51,15879 claims
Boehringer IngelheimJardiance$158$48,08540 claims
Johnson & JohnsonXarelto$65$25,73624 claims
MerckJanuvia$38$23,04419 claims
NovartisEntresto$119$20,95016 claims
AbbVieLinzess$783$15,42614 claims
Sanofi-aventis U.S. LLCLantus$131$5,20313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →